ACTH 1-39: The Full-Length Melanocortin Peptide in HPA Axis Research
16th Sep 2026

What You Need to Know About ACTH 1-39: The Full-Length Melanocortin Peptide in HPA Axis Research
- Researchers investigate ACTH 1-39 to understand how the pituitary gland communicates with the adrenal cortex during stress responses.
- It acts as the primary endogenous ligand for the melanocortin 2 receptor (MC2R), triggering intracellular cyclic AMP signalling cascades.
- Published studies observe that the first 24 amino acids drive receptor binding, while the remaining 15 residues stabilise the molecule against rapid enzymatic breakdown.
- Laboratory models utilise this full-length peptide to benchmark synthetic fragments and analyse systemic glucocorticoid release patterns.
How Full-Length ACTH 1-39 Drives Adrenal Signalling and Focus Pathways
ACTH 1-39 is the complete thirty-nine-amino-acid pituitary messenger that binds directly to adrenal melanocortin-2 receptors to trigger steroid hormone release and regulate cellular energy under stress. Because it carries both the active signalling core and the protective tail sequence, it serves as the benchmark reference for studying focus, stress recovery, and hypothalamic-pituitary-adrenal (HPA) axis communication.
To understand why researchers care about the full chain rather than just shorter fragments, it helps to look at how the molecule is built. The body slices ACTH 1-39 out of a much larger parent protein called pro-opiomelanocortin, or POMC, inside the anterior pituitary gland. Once released, this thirty-nine-amino-acid sequence acts like a two-part key. The first twenty-four amino acids at the front end handle the actual receptor binding and signal activation. Meanwhile, the remaining fifteen amino acids at the tail end act as a structural shield, protecting the peptide from rapid enzymatic breakdown while it travels to target tissues.
Unlike its shorter cousins, full-length ACTH 1-39 is the only melanocortin capable of unlocking the melanocortin-2 receptor (MC2R) on the outer cortex of the adrenal gland. To do this, it relies on a helper protein called MRAP, which guides the receptor to the cell surface. Once ACTH 1-39 docks, it flips an internal switch that boosts cyclic AMP (cAMP) levels inside the cell. This rapid rise in cAMP instructs the mitochondria to start converting cholesterol into pregnenolone, the starting block for glucocorticoids like cortisol and corticosterone.
Beyond the adrenal cortex, published studies show that the first thirteen amino acids of the chain also interact with MC1R, MC3R, MC4R, and MC5R receptors scattered across central nervous system tissues. In laboratory models examining neural focus, alertness, and stress adaptation, this secondary receptor activity is where researchers observe changes in synaptic plasticity, glial cell recovery, and inflammatory balance without relying solely on adrenal output.
ACTH 1-39 is not stocked as its own vial. Semax, an ACTH 4-10 heptapeptide analogue, and Selank are the closest stocked neuropeptides for next-day UK dispatch.
Browse Full UK Peptide Catalogue →What Published Studies Observe Across Minutes, Days, and Weeks
When investigators introduce ACTH 1-39 into preclinical models, the observed biological events split cleanly into two distinct phases: immediate biochemical signalling and slower structural adaptation. Because the peptide triggers a fast G-protein-coupled receptor response, the earliest readouts appear on a stopwatch rather than a calendar.
Within three to five minutes of exposure in isolated adrenal cell cultures, intracellular cAMP levels surge sharply. By the fifteen-to-thirty-minute mark, published studies record a peak in acute steroidogenesis, meaning the cells actively pump out newly synthesised glucocorticoids. During this first hour, researchers also track rapid phosphorylation of StAR (steroidogenic acute regulatory protein), the transport shuttling system that moves cholesterol across mitochondrial membranes. In neural tissue assays looking at focus and alertness markers, early immediate-early gene expression—such as c-Fos activation in hypothalamic nuclei—typically registers within forty-five to ninety minutes, before the free peptide is cleared by natural peptidases over the next two hours.
When study protocols shift from single exposures to repeated intervals over several days or weeks, the observations move from fast chemical sparks to physical tissue remodelling. Between days three and seven, laboratory models demonstrate measurable upregulation of the genes that build steroid-producing enzymes, specifically cytochrome P450 side-chain cleavage enzymes. Simply put, the cells do not just work faster; they build more factory equipment to handle future signals.
Across multi-week timelines—typically fourteen to twenty-eight days in rodent stress-recovery studies—investigators observe physical expansion and structural maintenance of the zona fasciculata, the middle layer of the adrenal cortex. At the same time, long-term studies track how sustained glucocorticoids feed back to the hypothalamus and pituitary to dial down native CRH release. Tracking both the fifteen-minute steroid spike and the fourteen-day receptor desensitisation window allows scientists to map the full rhythm of HPA axis exhaustion and recovery.
Structural and Functional Comparison of ACTH 1-39 and Related Melanocortin Fragments
| Peptide Variant | Amino Acid Length | Primary Receptor Affinity | Structural Role in Laboratory Models |
|---|---|---|---|
| ACTH 1-39 (Full-Length) | 39 residues | MC2R (plus MC1R, MC3R, MC4R, MC5R) | Baseline reference for complete endogenous adrenal signalling and peptide stability. |
| ACTH 1-24 (Tetracosactide) | 24 residues | MC2R (plus MC1R, MC3R, MC4R, MC5R) | Contains the active steroidogenic core without the C-terminal stabilising tail. |
| Alpha-MSH (ACTH 1-13) | 13 residues | MC1R, MC3R, MC4R, MC5R (No MC2R activity) | Evaluated for pigmentation, energy homeostasis, and inflammation signalling pathways. |
| ACTH 4-10 | 7 residues | MC3R, MC4R (Minimal MC2R binding) | Core heptapeptide sequence studied for neural signalling without adrenal stimulation. |
| CLIP (ACTH 18-39) | 22 residues | No direct melanocortin receptor activation | C-terminal cleavage product analysed in sleep-wake cycle and metabolic research. |
Complementary Peptides Studied Alongside ACTH 1-39 in HPA Models
No hormone in the HPA axis works in total isolation, which is why laboratory designs frequently pair ACTH 1-39 with upstream triggers, truncated fragments, or parallel pituitary secretagogues to see how different branches of the endocrine system talk to one another. When sourcing peptide hormones for multi-receptor assays, researchers usually build combinations around three specific questions: how the signal starts, how the brain responds independently of the adrenals, and how stress pathways cross-talk with growth pathways.
The most natural pairing in published studies is Corticotropin-Releasing Hormone (CRH) alongside ACTH 1-39. While CRH acts one step higher by telling pituitary corticotrophs to release native adrenocorticotropic hormone, running both peptides in parallel or sequential assays helps scientists pinpoint whether a signalling bottleneck sits in the pituitary gland or down in the adrenal cortex. Vasopressin (AVP) is occasionally added to these in vitro pituitary setups, as it naturally amplifies the CRH signal.
A second common laboratory strategy compares full-length ACTH 1-39 directly against shorter N-terminal fragments like ACTH 1-24 or the neuro-active heptapeptide analogue Semax (derived from ACTH 4-10). Because fragments covering positions four through ten lack the sequence needed to trigger adrenal cortisol release, running them side by side with full-length ACTH 1-39 lets researchers separate direct central nervous system effects—such as BDNF upregulation and synaptic repair—from steroid-driven effects.
Finally, endocrine researchers regularly examine the cross-talk between the HPA stress axis and the somatotropic growth axis by pairing ACTH 1-39 with a ghrp research peptide such as GHRP-6 or Ipamorelin. Published studies show that ghrelin mimetics do not just stimulate growth hormone release; they also nudge hypothalamic pathways that subtly modulate ACTH and cortisol pulses, making this combination useful for mapping how metabolic energy and stress recovery overlap.

Figure: ACTH 1-39: The Full-Length Melanocortin Peptide in HPA Axis Research
Why 99%+ HPLC Purity and Cold Storage Matter for a 39-Amino-Acid Chain
Synthesising a thirty-nine-amino-acid chain is noticeably trickier than putting together a short five- orseven-amino-acid peptide. Every single step in solid-phase synthesis carries a tiny chance of an incomplete coupling or a premature truncation. Over thirty-nine steps, those small errors can easily pile up, leaving a poorly purified batch littered with thirty-eight-mer or thirty-seven-mer deletion sequences that behave unpredictably on sensitive melanocortin receptors.
That is why verifying a minimum of 99%+ purity via High-Performance Liquid Chromatography (HPLC) and confirming the exact molecular weight (4541.1 Daltons) through Mass Spectrometry is essential for reliable laboratory work. If a vial contains leftover truncated sequences, those shorter fragments can bind to MC1R or MC4R receptors without activating MC2R, skewing the ratio between neural signalling and adrenal steroid output in an assay.
Equally important is the removal of trifluoroacetic acid (TFA) salts during the final polishing stages. Standard synthesis relies on TFA to cleave the peptide chain, but residual TFA ions are acidic and cytotoxic to delicate primary adrenal and neural cell cultures. Replacing harsh TFA counter-ions with benign acetate salts keeps pH levels stable and prevents cell membrane irritation from masquerading as peptide activity.
Because ACTH 1-39 contains a methionine residue at position four, it is also vulnerable to oxidation if left warm or exposed to light. Oxidation at that single methionine drastically drops its binding strength at the receptor. Before reconstitution, the lyophilised powder should be kept frozen at minus twenty degrees Celsius. Once mixed with a sterile bacteriostatic reconstitution solution, the liquid vial must be stored strictly between 2°C and 8°C in a dark laboratory refrigerator and used promptly before natural hydrolysis clips the protective C-terminal tail.
Frequently Asked Questions
Why is ACTH 1-39 studied so widely in HPA axis research?
Researchers search for ACTH 1-39 because it is the complete, thirty-nine amino acid chain that controls stress signalling in laboratory models. Unlike shorter synthetic fragments, this full-length melanocortin peptide activates all five melanocortin receptors, allowing scientists to analyse adrenal steroid release and cellular tissue recovery mechanisms.
What is the typical timeline observed in ACTH 1-39 laboratory studies?
In published studies, ACTH 1-39 triggers cellular signalling within minutes, though full protocol timelines often run from a few hours to several weeks. Acute experiments measure rapid glucocorticoid spikes over sixty to ninety minutes, while longer preclinical models track receptor desensitisation and gene expression across fourteen days.
Can ACTH 1-39 be combined with other peptides in research protocols?
Yes, laboratory protocols frequently pair ACTH 1-39 with corticotropin-releasing hormone (CRH) or shorter melanocortin fragments to map receptor pathways. Combining these compounds helps researchers compare how different protocol ratios influence adrenal cell output, inflammation signalling, and receptor binding without altering the baseline experimental environment.
What purity level and fridge storage conditions are required for ACTH 1-39?
Research-grade ACTH 1-39 requires a minimum purity of ninety-eight percent, verified by High-Performance Liquid Chromatography, and must be kept cold to prevent breakdown. Lyophilised powder stays stable in a freezer at minus twenty degrees Celsius, while liquid mixed with bacteriostatic reconstitution solution needs standard fridge storage between two and eight degrees.
Bibliography
- Gallo-Payet N, Payet MD. Mechanism of action of ACTH: beyond cAMP. Microsc Res Tech. 2003;61(3):275-287. View published research
- Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736-749. View published research
- Dores RM. Adrenocorticotropic hormone, melanocyte-stimulating hormone, and the melanocortin receptors: revisiting the work of Robert Schwyzer. Ann N Y Acad Sci. 2009;1163:93-100. View published research
- Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992;257(5074):1248-1251. View published research
- Fridmanis D, Roga A, Klovins J. ACTH Receptor (MC2R) Specificity: What Do We Know About It? Front Endocrinol (Lausanne). 2017;8:13. View published research
⚠️ Research Use Only Disclaimer: All peptides and compounds are sold strictly for in-vitro laboratory research purposes only. Not intended for human or veterinary use, not a dietary supplement, and not approved to diagnose, treat, cure, or prevent any disease or condition. For use by qualified researchers in suitably equipped laboratory environments only. Amino Peptides Ltd operates in full compliance with UK MHRA regulations and applicable EU research chemical guidelines.